These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 33825879)

  • 41. [SARS-CoV-2 Vaccination for Adult Patients with Inflammatory Bowel Disease: Expert Consensus Statements by KASID].
    Lee YJ; Kim SE; Park YE; Chang JY; Song HJ; Kim DH; Yang YJ; Kim BC; Lee JG; Yang HC; Choi M; Myung SJ;
    Korean J Gastroenterol; 2021 Aug; 78(2):117-128. PubMed ID: 34446634
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Confronting the Delta Variant of SARS-CoV-2, Summer 2021.
    Del Rio C; Malani PN; Omer SB
    JAMA; 2021 Sep; 326(11):1001-1002. PubMed ID: 34406361
    [No Abstract]   [Full Text] [Related]  

  • 43. Severe mental illness: reassessing COVID-19 vaccine priorities.
    Siva N
    Lancet; 2021 Feb; 397(10275):657. PubMed ID: 33610199
    [No Abstract]   [Full Text] [Related]  

  • 44. Business Not as Usual - Covid-19 Vaccination in Persons with Substance Use Disorders.
    Barocas JA
    N Engl J Med; 2021 Jan; 384(2):e6. PubMed ID: 33378604
    [No Abstract]   [Full Text] [Related]  

  • 45. Perspectives on COVID-19 vaccination for pregnant women in South Africa.
    Hunter M; Moodley J; Moran N
    Afr J Prim Health Care Fam Med; 2021 Jul; 13(1):e1-e3. PubMed ID: 34342475
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Shaping public opinion through the lens of agenda setting in rolling out COVID-19 vaccination program.
    Medina LM; Rodriguez JR; Sarmiento PJD
    J Public Health (Oxf); 2021 Jun; 43(2):e389-e390. PubMed ID: 33783540
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Covid-19 vaccine management (Comirnaty and mrna-1273 Moderna) in a teaching hospital in Italy: a short report on the vaccination campaign.
    Papini F; Grassi N; Guglielmi G; Gattini V; Rago L; Bisordi C; Scateni M; Totaro M; Tulipani A; Porretta A; Tavoschi L; Guercini J; Luchini G; Briani S; Privitera GP; Baggiani A
    Environ Health Prev Med; 2021 Sep; 26(1):99. PubMed ID: 34592930
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Quantitative serological evaluation as a valuable tool in the COVID-19 vaccination campaign.
    Ferrari D; Mangia A; Spanò MS; Zaffarano L; Viganò M; Di Resta C; Locatelli M; Ciceri F; De Vecchi E
    Clin Chem Lab Med; 2021 Nov; 59(12):2019-2026. PubMed ID: 34614550
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A patient presenting with ARDS after COVID-19 vaccination: A COVID-19 case report.
    Sahin Tutak A; Söylemez F; Konuk HB; Çakmak E; Karakaya B; Doğan A; Sayiner HS; Aksöz S; Alev M
    J Infect Public Health; 2021 Oct; 14(10):1395-1397. PubMed ID: 34175235
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and politicisation.
    COCONEL Group
    Lancet Infect Dis; 2020 Jul; 20(7):769-770. PubMed ID: 32445713
    [No Abstract]   [Full Text] [Related]  

  • 51. Blood Donation during COVID-19 Vaccination drive - The Need for Concern.
    Suvvari TK; Kutikuppala LVS; Garikipati NA; Ponnaganti SVK; Kandi VR
    Transfus Clin Biol; 2021 Aug; 28(3):307-308. PubMed ID: 34116916
    [No Abstract]   [Full Text] [Related]  

  • 52. [Immune thrombocytopenia after BNT162b2 mRNA COVID-19 vaccination].
    Matsumura A; Katsuki K; Akimoto M; Sakuma T; Nakajima Y; Miyazaki T; Fujisawa S; Nakajima H
    Rinsho Ketsueki; 2021; 62(11):1639-1642. PubMed ID: 34866090
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Boosting the nation against covid-19: are the vaccination targets feasible?
    Osama T; Hodes S; Razai MS; Majeed A
    BMJ; 2021 Dec; 375():n3094. PubMed ID: 34911679
    [No Abstract]   [Full Text] [Related]  

  • 54. Multisystem Inflammatory Syndrome after SARS-CoV-2 Infection and COVID-19 Vaccination.
    Salzman MB; Huang CW; O'Brien CM; Castillo RD
    Emerg Infect Dis; 2021 Jul; 27(7):1944-1948. PubMed ID: 34034858
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Science and religion for COVID-19 vaccine promotion.
    Galang JRF
    J Public Health (Oxf); 2021 Sep; 43(3):e513-e514. PubMed ID: 33866364
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Risk of Resurgence in Vaccine-Preventable Infections Due to Coronavirus Disease 2019-Related Gaps in Immunization.
    Feldman AG; O'Leary ST; Danziger-Isakov L
    Clin Infect Dis; 2021 Nov; 73(10):1920-1923. PubMed ID: 33580243
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hypersensitivity Reactions to Vaccines: Current Evidence and Standards for SARS-CoV-2 Vaccines.
    Carvalho JC; Cunha F; Coutinho IA; Loureiro C; Faria E; Bom AT
    Acta Med Port; 2021 Jun; 34(7-8):541-547. PubMed ID: 34851819
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The world's largest COVID-19 vaccination campaign.
    Bagcchi S
    Lancet Infect Dis; 2021 Mar; 21(3):323. PubMed ID: 33639124
    [No Abstract]   [Full Text] [Related]  

  • 59. Key Guidelines in Developing a Pre-Emptive COVID-19 Vaccination Uptake Promotion Strategy.
    French J; Deshpande S; Evans W; Obregon R
    Int J Environ Res Public Health; 2020 Aug; 17(16):. PubMed ID: 32823775
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Key populations for early COVID-19 immunization: preliminary guidance for policy.
    Ismail SJ; Zhao L; Tunis MC; Deeks SL; Quach C;
    CMAJ; 2020 Nov; 192(48):E1620-E1632. PubMed ID: 33144317
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.